Pain in Medical Technology

International Journal of Occupational and Environmental Health Features Discovery of Asbestos-Related Pain Origin from Scientists at the Karmanos Cancer Institute in Detroit

DETROIT, July 20 /PRNewswire-USNewswire/ -- Scientists at the Barbara Ann Karmanos Cancer Institute's National Center for Vermiculite and Asbestos-Related Cancers (NCVAC) have discovered a probable reason for the unrelenting chest pain experienced in certain patients with asbestos-r...

Iontophoretic Drug Delivery System (IDDS) Containing Lidocaine and Epinephrine is Effective in Reducing Pain Associated With Insertion of an Intravenous Catheter in a Phase 2 Clinical Trial

SEATTLE, July 9 /PRNewswire/ -- Dharma Therapeutics, Inc., ("Dharma") Seattle, WA (a subsidiary of the Transcu Group Limited, a company listed on the Singapore Exchange Limited) announced that its improved active transdermal delivery technology, which administers lidocaine and epinephrine through ...

King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use

ACUROX(R) and EMBEDA (TM) Data Highlighted at the College on Problems of Drug Dependence Annual Meeting RENO, Nev., June 25 /PRNewswire/ -- King Pharmaceuticals, Inc. (NYSE: KG ) today announced that the Company is presenting safety and efficacy data for ACUROX(R) and EMBEDA(TM) (ALO-01...

Data Suggest Sodium Oxybate Significantly Improves Pain and the Core Symptoms of Fibromyalgia

PALO ALTO, Calif., June 15 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals' (Nasdaq: JAZZ ) sodium oxybate (JZP-6) demonstrated statistically significant and clinically meaningful improvement in pain and the core symptoms associated with fibromyalgia, according to Phase III data presented last we...

Feldenkrais(R) Movement Institute Announces Simple Non-Surgical Solutions for Jaw and Facial Pain (TMJ)

Do-It-Yourself exercises help reduce stress-related TMJ problems and create healthy, pain-free habits BERKELEY, Calif., May 18 /PRNewswire/ -- The Feldenkrais Movement Institute announces the release of The Intelligent Body(R) TMJ Program as part of its The Intelligent Body(R) DIY-ser...

Cadence Pharmaceuticals Submits Acetavance New Drug Application for the Treatment of Acute Pain and Fever

SAN DIEGO, May 14 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX ) announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational product candidate, Acetavance(TM) (intravenous acetaminophen), for...

Arcion Therapeutics' Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy

-Clinical Data Presented at American Pain Society Annual Meeting- BALTIMORE, May 7 /PRNewswire/ -- Arcion Therapeutics, Inc., a venture backed clinical stage biotechnology company that develops pain therapies, today announced the presentation of data demonstrating that its lead candidate, ARC...

Three Clinical Presentations on Tapentadol Extended Release Tablets for Chronic Pain Featured at 2009 American Pain Society Annual Meeting

Safety and Efficacy Data from Phase 3 Study will be Highlighted SAN DIEGO, May 7 /PRNewswire-USNewswire/ -- Chronic pain is a significant medical challenge in the United States, and chronic low back pain is the most common cause of disability in developed countries. An estimated 100 million A...

Chronic Ankle Pain May Be More Than Just a Sprain

New information indicates tendon injuries may be the culprit ROSEMONT, Ill., May 1 /PRNewswire-USNewswire/ -- Ankle sprains are a common injury after a fall, sudden twist or blow to the ankle joint. Approximately 40 percent of those who suffer an ankle sprain will e...

QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy

Primary Endpoints Met; Data Demonstrate MoxDuo(TM) IR Provides Better Tolerability Than Morphine and Oxycodone Alone SYDNEY, Australia and BEDMINSTER, N.J., April 20 /PRNewswire-FirstCall/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today the successful completion of a Phase 3 ...

Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments

CHADDS FORD, Pa., Feb. 10 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP ) announced today that it has signed two research collaboration agreements to develop novel treatments for pain and to discover potential treatments for cancer. The first collaboration, with Harvar...

Cymbalta(R) Significantly Reduced Osteoarthritis Knee Pain in New Study

INDIANAPOLIS, Jan. 30 /PRNewswire-FirstCall/ -- In a new study, Cymbalta (duloxetine HCl) 60-120 mg, taken once daily, reduced pain severity significantly, compared with placebo, in patients with osteoarthritis pain of the knee. Data from the 13-week randomized, double-blind, placebo-controlle...

Study Shows Leconotide, an Investigative Calcium Channel Blocker, Has Potential as a Selective, Efficacious, Non-Opioid Pain Treatment

HONOLULU, Jan. 28 /PRNewswire/ -- Results of a pre-clinical study of leconotide, an investigative calcium channel blocker, shows it has the potential to be safe, selective, and efficacious as a new non-opioid treatment for pain relief. It also holds promise in multiple drug delivery options i...

Study of Cannabinoid Medicine for Pain Found Patients Got 'High,' but Effects Not Related to Pain Relief

HONOLULU, Jan. 28 /PRNewswire/ -- Researchers at Brigham and Women's Hospital found that patients taking cannabinoid medicines for pain may be getting "high," but these effects were unrelated to relief from their pain symptoms. Results of their study, one of the first to examine the addictive...

Advances in Science and Treatment of Pain Presented at 25th Annual American Academy of Pain Medicine Meeting January 28 - 31, 2009

Further Understanding of Pain as a Disease Leads to Innovation in Treatment GLENVIEW, Ill., Jan. 26 /PRNewswire/ -- The American Academy of Pain Medicine's (AAPM) 2009 Annual Meeting - its 25th Anniversary - will take place in Hawaii this week with over 200 scientific posters, presentations a...

AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety

Results Show Successful Clinical Validation of Pharmacodynamic Effect REDWOOD CITY, Calif., Jan. 12 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc., an emerging specialty pharmaceutical company focused on the treatment of intermittent and acute medical conditions with an initial emphasis on pain...

Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period

Results of FLEXX Trial Presented at the Osteoarthritis Research Society International's 2008 World Congress PARSIPPANY, N.J., Oct. 7 /PRNewswire/ -- Ferring Pharmaceuticals Inc. recently presented results from the FLEXX Trial of Osteoarthritis of the Knee, showing that EUFLEXXA(R) (1% sodium...

Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting

BRIDGEWATER, N.J., Sept. 9 /PRNewswire-FirstCall/ -- Alpharma Inc. (NYSE: ALO ), a global specialty pharmaceutical company, today announced results from its Phase III pivotal efficacy trial that showed ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochl...

Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company

Company Focuses Operations, Updates Zingo Launch Progress and Adlea Registration Strategy Conference Call Today at 11:30 am ET SOUTH SAN FRANCISCO, Calif., Sept. 3 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV ) announced today that the compa...

Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin

OSLO, August 28 /PRNewswire-FirstCall/ -- - Results Further Support the Clinical Profile of This Novel Anti-Cancer Agent Under Development to Improve the Survival of Patients With Hormone Refractory Prostate Cancer (HRPC) Algeta ASA (OSE: ALGETA), the Norwegian cancer therapeutics company,...

Shingles Pain Treatment Will Benefit More Patients

LONDON, August 21 /PRNewswire/ -- The medicated pain relief plaster, (Versatis) is now approved by the Scottish Medicines Consortium (SMC) for restricted use within NHS Scotland for patients suffering pain following shingles(1) http://www.scottishmedicines.org.uk/smc/5850.html . This reversal...

June 2008 Mayo Clinic Women's HealthSource Highlights Shingles Vaccine for Pain Prevention, Tips to Avoid Antibiotic Resistant Infections, and Benefits of Broad Genetic Testing

ROCHESTER, Minn., June 24 /PRNewswire-USNewswire/ -- Here are highlights from the June issue of Mayo Clinic Women's HealthSource. You may cite this publication as often as you wish. Mayo Clinic Women's HealthSource attribution is required. Reprinting is allowed for a fee. Include the following...

Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study

Patients on Treatment Also Experienced Improved Physical Functioning INDIANAPOLIS, June 13 /PRNewswire-FirstCall/ -- New data suggest that patients with osteoarthritis pain of the knee treated with 60 mg and 120 mg Cymbalta (duloxetine HCl) once daily experienced significant pain reduction. ...

Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration

INDIANAPOLIS, May 29 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY ) has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for a new indication for Cymbalta(R) (duloxetine HCl) for the management of chronic pain, ...

QRxPharma Releases Additional Phase 3 Data for Q8003IR 'Dual Opioid' Pain Therapy

Establishes Preferred Dose for Optimal Efficacy and Tolerability; Study Goals and Secondary Endpoints Met SYDNEY, Australia and BEDMINSTER, N.J., May 22 /PRNewswire-FirstCall/ -- QRxPharma Limited (ASX: QRX), a clinical-stage specialty pharmaceutical company focused on the development and com...

Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile

TAMPA, Fla., May 9 /PRNewswire-USNewswire/ -- Osteoarthritis is a painful and potentially debilitating condition that affects almost 50 million people in the United States. It is caused by deterioration of cartilage in bone joints. The novel investigational pain medication tapentadol, a central...

New Study Suggests Tapentadol IR for Acute Pain Is Associated With Improved Gastrointestinal Tolerability Compared to Oxycodone IR

TAMPA, Fla., May 9 /PRNewswire-USNewswire/ -- Many strong acting pain medications have bothersome side effects. These can include nausea and vomiting with short-term use, and constipation with longer, chronic use. Such symptoms can lead patients to discontinue treatment, adding additional comp...

New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery

Novel Pain Medicine Studied in Patients Following Bunionectomy TAMPA, Fla., May 9 /PRNewswire-USNewswire/ -- Many foot-surgery patients experience intense pain for several days following removal of a bunion, one of the most common foot surgeries. The investigational pain medication tapen...

Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session

TAMPA, Fla., May 8 /PRNewswire-FirstCall/ -- Alpharma Inc. (NYSE: ALO ), a global specialty pharmaceutical company, today announced results from clinical trials that showed ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) capsules demonstrated ...

Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions

Patch Formulation May Provide New Option for Clinicians Concerned About Systemic Exposure When Using an Oral NSAID TAMPA, Fla., May 8 /PRNewswire-FirstCall/ -- Alpharma Inc. (NYSE: ALO ), a leading global specialty pharmaceutical company, announced today that two studies to be p...

Johnson & Johnson to Provide Webcast Presentation of Tapentadol Phase 3 Clinical Data Presented at American Pain Society's Annual Meeting

NEW BRUNSWICK, N.J., May 7 /PRNewswire-FirstCall/ -- Johnson & Johnson will provide a pre-recorded webcast for financial analysts on Friday, May 9 at 4:00 p.m. (Eastern Time) to coincide with the American Pain Society's (APS) annual meeting in Tampa, Fla. Phase 3 clinical data presentations on...

NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting

SAN CARLOS, Calif., May 7 /PRNewswire-FirstCall/ -- New Phase 1 clinical trial results for NKTR-118 (oral PEG-naloxol) were presented by Nektar Therapeutics (Nasdaq: NKTR ) this week at the Annual Meeting of the American Pain Society (APS) in Tampa, Florida. In this multiple-dose Phase 1 stud...

QRxPharma Releases Successful Phase 3 Study Results for 'Dual Opioid' Pain Therapy

Q8003IR Met Primary Endpoints; Demonstrated Strong Reduction of Pain Intensity SYDNEY, Australia and BEDMINSTER, N.J., May 5 /PRNewswire-FirstCall/ -- QRxPharma Limited (ASX: QRX), a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of thera...

Data Presented at AAN Show That Lacosamide Significantly Reduced Pain and was Generally Well Tolerated in Patients With Diabetic Neuropathic Pain

UCB announces clinical data presented at the 60th Annual Meeting of the American Academy of Neurology (AAN) in Chicago SMYRNA, Ga., April 16 /PRNewswire/ -- UCB presented efficacy and safety results from pooled analyses of Phase II and III double-blind, randomized, placebo-controll...

Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement

SOUTH SAN FRANCISCO, Calif., April 8, 2008 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV ) today announced that a pivotal Phase 3 clinical trial evaluating Adlea(TM), its long-acting, non-opioid analgesic drug candidate, in patients following total knee replacement surgery, is underwa...

Most Back Pain Could Be Cured Without Surgery or Drugs if Doctors Treated Muscles - Not the Spine - Says Leading Pain Specialist

NEW YORK, April 8, 2008 /PRNewswire/ -- If you're suffering from back pain and unable to find relief, it may be because the real cause of your pain -- weak, stressed and damaged muscles, not your spine -- has never been recognized or treated, says Norman Marcus, M.D., one of the nation's leadi...

Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program

LA JOLLA, Calif., April 7, 2008 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP) announced today that based on the U.S. Food and Drug Administration's ("FDA") review of its Phase 3 submission the Company can initiate its Phase 3 clinical program for its novel...

CV Therapeutics' Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina

CHICAGO, April 1, 2008 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX ) today announced new data presented at the 57th Annual Scientific Sessions of the American College of Cardiology shows that Ranexa(R) (ranolazine extended release tablets) significantly reduced the risk of r...

Kingfisher Announces FDA 510(k) Clearance of Breakthrough KFH Energy for Chronic Pain Sufferers

Kingfisher's Revolutionary Device Designed to Improve Quality of Life for Patients Suffering From Chronic Pain ALBUQUERQUE, New Mexico, March 31 /PRNewswire/ -- Kingfisher Americas, a healthcare company focused on improving patient quality of life, announced today that the U.S....

Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy

SOUTH SAN FRANCISCO, Calif., March 25 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV ) today announced the initiation of a pivotal Phase 3 trial evaluating Adlea(TM), its long-acting, non-opioid analgesic drug candidate, in patients following bunionectomy surgery. The multicenter, doub...